Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Development of colorectal cancer miRNA expression signatures from expression profiles of embryonic development, precancer progression and cancer samples

ABSTRACT: To further development of our gene expression signature for survival prediction, we conducted expression profiles of embryonic development, precancer progression and cancer samples.

ORGANISM(S): Homo sapiens

PROVIDER: GSE71130 | GEO | 2017/02/09

SECONDARY ACCESSION(S): PRJNA290403

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Development of colorectal cancer gene expression signatures from expression profiles of embryonic development, precancer progression and cancer samples

Project description:To further development of our gene expression signature for survival prediction, we conducted expression profiles of embryonic development, precancer progression and cancer samples.

2017-02-09 | GSE71187 | GEO

Temporal recording of mammalian development and precancer

Project description:Temporal recording of mammalian development and precancer

| PRJNA984615 | ENA

Temporal recording of mammalian development and precancer [WES]

Project description:Temporal recording of mammalian development and precancer [WES]

| PRJNA984620 | ENA

Temporal recording of mammalian development and precancer [rna-seq]

Project description:Temporal recording of mammalian development and precancer [rna-seq]

| PRJNA983786 | ENA

Spatiotemporally Deciphering the Unknown Role of Persistent HPV Infection in Precancer to Cervical Cancer Progression: Integrating Single-Cell RNA-Sequencing Landscape and Spatial Transcriptomics Atlas [Spatial Transcriptomics]

Project description:The mechanism underlying the cervical carcinogenesis mediated by persistent HPV infection remains elusive. Here we pioneeringly deciphered both temporal transition and spatial distribution of the cellular subsets during the disease progression from normal cervix, precancer lesions to cervical cancer by integrating scRNA-seq with ST. We not only identified three ‘HPV-related epithelial clusters’ unique to normal, HSIL and cervical cancer respectively, but also discovered node genes which potentially determined the disease progression. Moreover, we observed a gradual transition of multiple immune cells from positive immune response to dysregulation and exhaustion, to an immune-suppressive microenvironment during the malignant program. Besides, the cellular interaction analysis further verified a ‘homeostasis-balance-malignancy’ change within cervix microenvironment during disease escalation. Together, these findings not only deciphered mysterious persistent HPV infection spatiotemporally from the process of precancer to cervical cancer but also provided unprecedented possibilities for accurate diagnosis, precise treatment and prognosis evaluation for precancer and cervical cancer.

2023-04-02 | GSE208654 | GEO

2023-04-02 | GSE208653 | GEO

Gene expression of CD66 expressing cells in cervical precancer cell line

Project description:Gene Expression profiles of sorted CD66High and CD66Low cells were generated from CIN612-9E cells grown in Emedia. We have analyzed the gene expression pattern of CD66High and CD66Low cells from CIN612 9E. These cells are derived from a cervical precancer lesion (M. Bedell, J. Hudson, T. Golub et al, 1991, J. Virol) Two sets of experiments (biological replicates) were performed for CD66High and CD66Low cells.

2014-09-30 | E-GEOD-59322 | biostudies-arrayexpress

A trial to establish whether laser treatment of anal precancer prevents development of anal cancer in HIV-positive men who have sex with men

Project description:Background and study aims Anal cancer is a growing problem in the UK. Almost 90% of these cancers are caused by the human papillomavirus (HPV). HPV infection in a weakened immune system can lead to abnormal cell changes which are graded as anal intraepithelial neoplasia (AIN) 1-3, with AIN 2 and AIN 3 considered to be high-grade neoplasia (AIN 2/3). These changes are called precancers, but it is not known how many, over what time period will turn to cancer. Although many doctors and scientists think we need to treat AIN 2/3 (precancer), as is done in women for cervical precancer to prevent cancer, there is no proven treatment for anal precancer (AIN 2/3) that will prevent anal cancer. Laser treatment may be an effective strategy to prevent anal cancer. The main aim of the study is to assess the long-term effect (up to 5 years) of laser treatment in preventing anal cancer in HIV-positive men who have sex with men with anal precancer. Who can participate? HIV-positive men who have sex with men, who have anal precancer What does the study involve? Participants are randomly allocated to one of two groups. Participants in the treatment group undergo laser ablation of their perianal (external) or anal canal (internal) disease under local anaesthetic injections. If the disease volume (extent) is large the ablation may be done under general anaesthetic as a day case. Rarely, it may be necessary to treat extensive disease as a staged procedure over more than one treatment visit. Participants in the active surveillance group receive no treatment. All participants are followed up every 6 months with standard examinations. The number of cancers, the effect of treatment on preventing new precancer, quality of life, and the costs of treatment are compared between the groups.

| 2410507 | ecrin-mdr-crc

Gene expression of CD66 expressing cells in cervical precancer cell line

2014-09-30 | GSE59322 | GEO

Development of complete personalized treatment plans for early stage colorectal cancer patients

Project description:593 FFPE colorectal cancer samples were used to generate three prediction models: Recurrence prediction, 5FU efficacy prediction, and FOLFOX efficacy prediction The recurrence prediction study has 235 samples , 5FU efficacy prediction study has 192 samples, FOLFOX had 166 samples

2017-06-10 | GSE81653 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data